Tafasitamab, Lenalidomide, Rituximab, and Orelabrutinib for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
A Prospective, Multicenter, Phase II Clinical Study of Tafasitamab, Lenalidomide, Rituximab, and Orelabrutinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
This is a Phase II, Single-Arm, Open-Label, Prospective, Multicentre Study to Evaluate the Safety and Efficacy of Tafasitamab (TAFA) combined with Lenalidomide, Rituximab, and Orelabrutinib in Participants with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL).
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Qingqing Cai
- Telefonnummer: 020-87342823
- E-mail: caiqq@sysucc.org.cn
Studiesteder
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510000
- The Sixth Affiliated Hospital, Sun Yat-sen University
-
Kontakt:
- Ning Su
-
Guangzhou, Guangdong, Kina, 510000
- Sun Yat-sen Univercity Cancer Center, Sun Yat-sen University
-
Kontakt:
- Qingqing Cai
- Telefonnummer: 020-87342823
- E-mail: caiqq@sysucc.org.cn
-
Guangzhou, Guangdong, Kina, 510000
- The Fifth Affiliated Hospital of Guangzhou Medical University
-
Kontakt:
- Runhui Zheng
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Willing to participate in the clinical study and signed informed consent.
- Age ≥18 years, no gender restrictions.
- Histologically confirmed relapsed or refractory diffuse large B-cell lymphoma; ineligible for or unable to access autologous stem cell transplantation (ASCT), chimeric antigen receptor T-cell (CAR-T) therapy.
- Has at least one measurable or assessable lesion.
- Eastern Cooperative Oncology Group performance status (ECOG PS) score ≤
- Adequate major organ function.
Exclusion Criteria:
- DLBCL with central nervous system involvement or Burkitt lymphoma.
- Disease progression following prior frontline treatment with a Bruton tyrosine kinase inhibitor (BTKi).
- Active human immunodeficiency virus (HIV) or hepatitis C virus (HCV) infection.
- Inability to swallow capsules or significant gastrointestinal impairment that may affect drug absorption.
- Other progressive malignancy requiring active treatment.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Tafasitamab in combination with Lenalidomide, Rituximab and Orelabrutinib
Participants will receive tafasitamab in combination with lenalidomide, rituximab and orelabrutinib for 4 cycles, and then receive tafasitamab and lenalidomide for additional 8 cycles. Each treatment cycle is 28 days. |
12mg/kg, IV, C1-3: D1, 8, 15, 22 (with an additional loading dose on C1D4), C4-12: D1, 15. 25mg, PO, day 1-21 of cycle 1-12 375mg/m2, IV, day 1 of cycle 1-4 150mg or 100mg, PO, day 1-28 of cycle 1-4 |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Complete response rate (CRR)
Tidsramme: Up to 12 cycles ( each cycle is 28 days)
|
CRR was defined as the proportion of patients who achieve complete response (CR) |
Up to 12 cycles ( each cycle is 28 days)
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Objective response rate (ORR)
Tidsramme: Up to 12 cycles (each cycle is 28 days)
|
ORR was defined as the proportion of patients who achieve complete response (CR) or partial response (PR) |
Up to 12 cycles (each cycle is 28 days)
|
|
Disease control rate (DCR)
Tidsramme: Up to 12 cycles (each cycle is 28 days)
|
DCR was defined as the proportion of patients who achieve complete response (CR), partial response (PR) and stable disease (SD) |
Up to 12 cycles (each cycle is 28 days)
|
|
Duration of Response (DoR)
Tidsramme: up to 3 years
|
DoR was defined as the time from the patients's first efficacy assessment achieving CR or PR until disease progression |
up to 3 years
|
|
Duration of Complete Response (DoCR)
Tidsramme: up to 3 years
|
DoCR was defined as the time from the patients's first efficacy assessment achieving CR until disease progression |
up to 3 years
|
|
Progression-free survival (PFS)
Tidsramme: up to 3 years
|
PFS was defined as the time from the date of the first administration of any study drug to the date of tumor progression or death from any cause |
up to 3 years
|
|
Overall survival (OS)
Tidsramme: up to 3 years
|
OS was defined as the time from the date of the first administration of any study drug until death from any cause |
up to 3 years
|
|
Time to Response (TTR)
Tidsramme: Up to 12 cycles (each cycle is 28 days)
|
TTR was defined as the time from the initiation of treatment to the patients's first efficacy assessment achieving CR or PR |
Up to 12 cycles (each cycle is 28 days)
|
|
Adverse events
Tidsramme: Up to 28 days after the last dose of study drug
|
The incidence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs) |
Up to 28 days after the last dose of study drug
|
|
Change in Quality of Life
Tidsramme: Up to 3 years
|
Quality of life will be assessed using the EORTC QLQ-C30 questionnaire |
Up to 3 years
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Neoplasmer
- Sygdomme i immunsystemet
- Neoplasmer efter histologisk type
- Lymfesygdomme
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Lymfom, Non-Hodgkin
- Lymfom, B-celle
- Lymfom
- Hemiske og lymfatiske sygdomme
- Lymfom, stor B-celle, diffus
- Aminosyrer, peptider og proteiner
- Proteiner
- Organiske kemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ring
- Carboxylsyrer
- Piperidiner
- Antistoffer, monoklonal
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serum globuliner
- Globuliner
- Antistoffer, monoklonal, murint afledt
- Phthalimider
- Phthalinsyrer
- Syrer, carbocykliske
- Piperidones
- Isoindoler
- Lenalidomid
- Rituximab
- Tafasitamab
- Orelabrutinib
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- B2026-526
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .